Related Experiment Videos
Fluoroquinolones in the treatment of cystic fibrosis
N Høiby1, S S Pedersen, T Jensen
1Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
Abstract:
Cystic fibrosis patients suffer from recurrent and chronic lung infections mainly caused by Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa. The fluoroquinolones, notably ciprofloxacin and ofloxacin, represent an important addition to the therapy of P. aeruginosa infections. They offer the possibility of effective oral treatment for early colonisation as well as chronic infections, even in children. They are associated with only few and mild adverse effects. Development of resistance represents an increasing problem.
Insights
Fluoroquinolones like ciprofloxacin are effective oral treatments for Pseudomonas aeruginosa lung infections in cystic fibrosis patients. However, the increasing development of bacterial resistance is a growing concern for this important therapy.
Area of Science:
- Medical Microbiology
- Pulmonology
- Infectious Diseases
Background:
- Cystic fibrosis (CF) patients experience frequent lung infections.
- Key pathogens include Staphylococcus aureus, Haemophilus influenzae, and Pseudomonas aeruginosa.
- Pseudomonas aeruginosa is a major cause of morbidity and mortality in CF.
Purpose of the Study:
- To evaluate the role of fluoroquinolones in treating P. aeruginosa infections in CF.
- To assess the efficacy and safety of oral fluoroquinolones for CF lung infections.
- To highlight the challenge of antimicrobial resistance.
Main Methods:
- Review of existing literature on fluoroquinolone use in CF.
- Analysis of treatment outcomes for P. aeruginosa infections.
- Assessment of adverse effects and resistance patterns.
Main Results:
- Fluoroquinolones (ciprofloxacin, ofloxacin) provide effective oral therapy for P. aeruginosa.
- Treatment is suitable for early colonization and chronic infections, including in children.
- Adverse effects are generally mild.
- Increasing bacterial resistance to fluoroquinolones is a significant issue.
Conclusions:
- Fluoroquinolones are valuable for managing P. aeruginosa in CF.
- Oral administration offers treatment convenience.
- Antimicrobial stewardship is crucial due to rising resistance.